Dashboard
Manage Tickers

BBIO BridgeBio Pharma, Inc.

Nasdaq bridgebio.com


$ 56.51 $ 0.54 (0.96 %)    

Tuesday, 14-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 56.5
$ 55.95
$ 51.74 x 4
$ 57.48 x 1,018
$ 55.41 - $ 57.47
$ 21.72 - $ 57.47
2,490,213
na
10.8B
$ 1.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 04-29-2025 03-31-2025 10-Q
3 02-20-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-11-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-03-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bridgebios-acoramidis-cuts-risk-within-weeks-in-rare-heart-condition
BridgeBio's Acoramidis Cuts Risk Within We...
09/29/2025 14:42:14

BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study.

reported-sunday-bridgebio-pharma-says-acoramidis-prevented-53-cardiovascular-events-per-100-patients-at-month-30-in-attribute-cm-study
Reported Sunday, BridgeBio Pharma Says Aco...
09/29/2025 06:36:55

By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placeboAcoramidis significantly reduc...

bridgebio-pharma-to-highlight-one-late-breaking-clinical-trials-oral-presentation-one-oral-presentation-and-three-poster-sessions-at-hfsa-asm-2025
BridgeBio Pharma To Highlight One Late Bre...
09/22/2025 11:34:16

hc-wainwright--co-reiterates-buy-on-bridgebio-pharma-maintains-70-price-target
HC Wainwright & Co. Reiterates Buy on Brid...
09/15/2025 11:50:33

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $70 pr...

ubs-maintains-buy-on-bridgebio-pharma-raises-price-target-to-82
UBS Maintains Buy on BridgeBio Pharma, Rai...
09/12/2025 14:26:55

UBS analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $72 to $82.

Core News & Articles
'BridgeBio Says Pfizer, Alnylam Aren't Pla...
09/11/2025 18:47:11

https://www.bloomberg.com/news/articles/2025-09-11/bridgebio-says-pfizer-alnylam-aren-t-playing-fair-in-blockbuster-race?embedd...

bridgebio-pharma-announced-that-encaleret-showed-parathyroid-hormone-independent-normalization-of-blood-and-urine-calcium-in-post-surgical-hypoparathyroidism-in-phase-2-trial
BridgeBio Pharma Announced That Encaleret ...
09/07/2025 16:23:15

80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal referen...

jp-morgan-maintains-overweight-on-bridgebio-pharma-raises-price-target-to-70
JP Morgan Maintains Overweight on BridgeBi...
09/03/2025 14:49:02

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $5...

hc-wainwright--co-reiterates-buy-on-bridgebio-pharma-maintains-70-price-target
HC Wainwright & Co. Reiterates Buy on Brid...
09/03/2025 10:51:25

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $70 pr...

bridgebio-to-present-encaleret-phase-2-proof-of-concept-data-at-asbmr-annual-meeting-sept-5-8
BridgeBio To Present Encaleret Phase 2 Pro...
09/02/2025 11:34:31

reported-saturday-bridgebios-attrubybeyonttra-reports-significant-42-month-cv-mortality-reduction-in-attribute-cm-open-label-extension
Reported Saturday, BridgeBio's Attruby/BEY...
09/02/2025 07:50:51

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduct...

hc-wainwright--co-maintains-buy-on-bridgebio-pharma-raises-price-target-to-70
HC Wainwright & Co. Maintains Buy on Bridg...
08/29/2025 18:21:30

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price ...

bridgebio-to-present-new-acoramidis-data-showing-reduced-cardiovascular-death-risk-at-esc-2025
BridgeBio to Present New Acoramidis Data S...
08/25/2025 11:46:57

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company fo...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
08/13/2025 17:35:30

scotiabank-maintains-sector-outperform-on-bridgebio-pharma-raises-price-target-to-57
Scotiabank Maintains Sector Outperform on ...
08/06/2025 16:25:44

Scotiabank analyst Greg Harrison maintains BridgeBio Pharma (NASDAQ:BBIO) with a Sector Outperform and raises the price targ...

oppenheimer-maintains-outperform-on-bridgebio-pharma-raises-price-target-to-61
Oppenheimer Maintains Outperform on Bridge...
08/06/2025 12:10:39

Oppenheimer analyst Leland Gershell maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target f...

bridgebio-pharma-q2-eps-095-misses-081-estimate-sales-110565m-beat-100424m-estimate
BridgeBio Pharma Q2 EPS $(0.95) Misses $(0...
08/05/2025 20:02:34

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

Core News & Articles
10 Health Care Stocks Whale Activity In To...
07/30/2025 17:35:27

cantor-fitzgerald-reiterates-overweight-on-bridgebio-pharma-maintains-95-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/29/2025 14:18:39

Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $95 price ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION